title: Children's Oncology Group's 2013 blueprint for research: Soft tissue sarcomas.
abstract: In the US, approximately 850-900 children are diagnosed each year with soft tissue sarcomas (STS). Key findings from recent Children's Oncology Group (COG) clinical trials include safe reduction in therapy for low risk rhabdomyosarcoma (RMS), validation of FOXO1 fusion as a prognostic factor, a modest improvement in outcome for high-risk RMS, and a biologically designed non-cytotoxic therapy for pediatric desmoid tumor. Planned Phase 2 trials include targeted agents for VEGF/PDGF, mTOR, and IGF-1R for children with RMS and VEGF for children with non-RMS STS (NRSTS). For RMS, COG Phase 3 trials potentially will explore VEGF/mTOR inhibition or chemotherapy interval compression. For NRSTS, a COG Phase 3 trial will explore VEGF inhibition.
authors.affiliation: Seattle Children's Hospital, University of Washington, and Fred Hutchinson Cancer Research Center, Seattle, WA 98015, USA. doug.hawkins@seattlechildrens.org
authors.forename: Douglas S
authors.initials: DS
authors.lastname: Hawkins
authors.forename: Sheri L
authors.initials: SL
authors.lastname: Spunt
authors.forename: Stephen X
authors.initials: SX
authors.lastname: Skapek
mesh_terms: D000970:Antineoplastic Agents / Q000627:therapeutic use; D002648:Child; D002986:Clinical Trials as Topic; D003131:Combined Modality Therapy; D006801:Humans; D011878:Radiotherapy; D012106:Research; D012509:Sarcoma / Q000235:genetics* / Q000473:pathology* / Q000628:therapy*
chemical_list: D000970:Antineoplastic Agents